Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11850319 | 0.98 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3OPRD1 | |
| SCHEMBL28296797 | 0.89 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10405701 | 0.85 | IDO1 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28046490 | 0.85 | IDO1 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20883793 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2247018 | 0.83 | OPRD1 (0.57) | SLC6A2SLC6A4SLC6A3OPRD1 | |
| SCHEMBL22542178 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3OPRD1 | |
| SCHEMBL22851498 | 0.82 | OPRD1 (0.47) | SLC6A2SLC6A4SLC6A3OPRD1 | |
| Hydrochloric Acid SCHEMBL3657538 | 0.82 | OPRD1 (0.56) | SLC6A2SLC6A4SLC6A3OPRD1 | |
| SCHEMBL29054036 | 0.81 | GAA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2390248-A1 | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | FAES FARMA, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
| EP-1328514-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
| US-3992546-A | 4-Piperidinobutyrophenones as neuroleptics | CIBA-GEIGY CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SLC6A2 1283/4885SLC6A4 523/4885SLC6A3 646/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SLC6A2 1697/4885SLC6A4 675/4885SLC6A3 1140/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SLC6A2 1461/4885SLC6A4 611/4885SLC6A3 839/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SLC6A2 1325/4885SLC6A4 528/4885SLC6A3 656/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | SLC6A2 2774/4885SLC6A4 1341/4885SLC6A3 1834/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | SLC6A2 4290/4885SLC6A4 4613/4885SLC6A3 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.